Literature DB >> 35530641

ZAP70 Activation Compensates for Loss of Class IA PI3K Isoforms Through Activation of the JAK-STAT3 Pathway.

Melike Demir1, Onur Cizmecioglu1.   

Abstract

BACKGROUND/AIM: Tyrosine kinases have crucial functions in cell signaling and proliferation. The phosphatidylinositol 3-kinase (PI3K) pathway is frequently deregulated in human cancer and is an essential regulator of cellular proliferation. We aimed to determine which tyrosine kinases contribute to resistance elicited by PI3K silencing and inhibition.
MATERIALS AND METHODS: To mimic catalytic inactivation of p110α/β, specific p110α (BYL719) and p110β (KIN193) inhibitors were used in addition to genetic knock-out in in vitro assays. Cell viability was assessed using crystal violet staining, whereas cellular transformation ability was analyzed by soft-agar growth assays.
RESULTS: Activated zeta chain of T-cell receptor-associated protein kinase 70 (ZAP70) generated resistance to PI3K inhibition. This resistance was via activation of the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) axis. We demonstrated that activated ZAP70 has a high transforming capability associated with the formation of malignant phenotype in untransformed cells and has the potential to be a tumor-initiating factor in cancer cells.
CONCLUSION: ZAP70 may be a potent driver of proliferation and transformation in untransformed cells and is implicated in resistance to PI3K inhibitors in cancer cells. Copyright 2022, International Institute of Anticancer Research.

Entities:  

Keywords:  PI3K; ZAP70; cell signaling; growth resistance; tyrosine kinases

Year:  2022        PMID: 35530641      PMCID: PMC9066532          DOI: 10.21873/cdp.10122

Source DB:  PubMed          Journal:  Cancer Diagn Progn        ISSN: 2732-7787


  46 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

2.  Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

Authors:  Dejan Juric; Jordi Rodon; Josep Tabernero; Filip Janku; Howard A Burris; Jan H M Schellens; Mark R Middleton; Jordan Berlin; Martin Schuler; Marta Gil-Martin; Hope S Rugo; Ruth Seggewiss-Bernhardt; Alan Huang; Douglas Bootle; David Demanse; Lars Blumenstein; Christina Coughlin; Cornelia Quadt; José Baselga
Journal:  J Clin Oncol       Date:  2018-02-05       Impact factor: 44.544

Review 3.  Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells.

Authors:  Elzbieta Gocek; Anargyros N Moulas; George P Studzinski
Journal:  Crit Rev Clin Lab Sci       Date:  2014-01-22       Impact factor: 6.250

4.  Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.

Authors:  Xiuning Le; Rajee Antony; Pedram Razavi; Daniel J Treacy; Flora Luo; Mahmoud Ghandi; Pau Castel; Maurizio Scaltriti; Jose Baselga; Levi A Garraway
Journal:  Cancer Discov       Date:  2016-09-07       Impact factor: 39.397

5.  Absolute lymphocyte count with extreme hyperleukocytosis does not have a prognostic impact in chronic lymphocytic leukemia.

Authors:  Lev Shvidel; Osnat Bairey; Tamar Tadmor; Andrei Braester; Rosa Ruchlemer; Riva Fineman; Erel Joffe; Alain Berrebi; Aaron Polliack
Journal:  Anticancer Res       Date:  2015-05       Impact factor: 2.480

Review 6.  Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors.

Authors:  Ariella B Hanker; Virginia Kaklamani; Carlos L Arteaga
Journal:  Cancer Discov       Date:  2019-03-13       Impact factor: 39.397

Review 7.  Targeting the phosphoinositide 3-kinase pathway in cancer.

Authors:  Pixu Liu; Hailing Cheng; Thomas M Roberts; Jean J Zhao
Journal:  Nat Rev Drug Discov       Date:  2009-08       Impact factor: 84.694

Review 8.  SRC family kinases: potential targets for the treatment of human cancer and leukemia.

Authors:  Markus Warmuth; Robert Damoiseaux; Yi Liu; Doriano Fabbro; Nathanael Gray
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

9.  Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN loss.

Authors:  Onur Cizmecioglu; Jing Ni; Shaozhen Xie; Jean J Zhao; Thomas M Roberts
Journal:  Elife       Date:  2016-10-04       Impact factor: 8.140

Review 10.  Beyond TCR Signaling: Emerging Functions of Lck in Cancer and Immunotherapy.

Authors:  Ursula Bommhardt; Burkhart Schraven; Luca Simeoni
Journal:  Int J Mol Sci       Date:  2019-07-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.